Brief: Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Relmada Therapeutics

04/12/2024 12:47

Dec 4 (Reuters) - Relmada Therapeutics Inc  RLMD.O :
    * RELMADA THERAPEUTICS REPORTS THAT DATA MONITORING
COMMITTEE
(DMC) ASSESSMENT INDICATES THAT THE PHASE 3 RELIANCE II TRIAL IS
FUTILE AT ITS INTERIM ANALYSIS AND IS UNLIKELY TO MEET THE
PRIMARY EFFICACY ENDPOINT WITH STATISTICAL SIGNIFICANCE
    * RELMADA THERAPEUTICS INC: TO CONTINUE TO FOCUS ON
DEVELOPMENT OF
REL-P11 FOR METABOLIC DISEASE
    * RELMADA THERAPEUTICS INC - TO EVALUATE NEXT STEPS FOR
REL-1017
PROGRAM
    * RELMADA THERAPEUTICS INC - TO FOCUS ON DEVELOPMENT OF
REL-P11
FOR METABOLIC DISEASE
    * RELMADA THERAPEUTICS INC - DMC DID NOT IDENTIFY ANY NEW
SAFETY
CONCERNS IN RELIANCE II STUDY

Source text:  ID:nGNX25W7V5 
Further company coverage:  RLMD.O 

 ((Reuters.Briefs@thomsonreuters.com;))